Your browser doesn't support javascript.
loading
Design of Nanotechnological Carriers for Ocular Delivery of Mangiferin: Preformulation Study.
Santonocito, Debora; Vivero-Lopez, Maria; Lauro, Maria Rosaria; Torrisi, Cristina; Castelli, Francesco; Sarpietro, Maria Grazia; Puglia, Carmelo.
Afiliación
  • Santonocito D; Department of Drug and Health Sciences, University of Catania, Viale Andrea Doria n 6, 95125 Catania, Italy.
  • Vivero-Lopez M; Departamento de Farmacología, Farmacia y Tecnología Farmacéutica, I+D Farma (GI-1645), Facultad de Farmacia and Health Research Institute of Santiago de Compostela (IDIS), Universidade de Santiago de Compostela, 15782 Santiago de Compostela, Spain.
  • Lauro MR; Department of Pharmacy, University of Salerno, Via Giovanni Paolo II, 84084 Fisciano, Italy.
  • Torrisi C; Department of Drug and Health Sciences, University of Catania, Viale Andrea Doria n 6, 95125 Catania, Italy.
  • Castelli F; Department of Drug and Health Sciences, University of Catania, Viale Andrea Doria n 6, 95125 Catania, Italy.
  • Sarpietro MG; NANO-i-Research Centre on Ocular Nanotechnology, University of Catania, 95125 Catania, Italy.
  • Puglia C; Department of Drug and Health Sciences, University of Catania, Viale Andrea Doria n 6, 95125 Catania, Italy.
Molecules ; 27(4)2022 Feb 16.
Article en En | MEDLINE | ID: mdl-35209120
(1) Background: Mangiferin (MGN) is a natural compound, showing anti-inflammatory and antioxidant activities for the potential treatment of eye diseases. The poor physicochemical features of MGN (low solubility and high instability) justify its nanoencapsulation into nanostructured lipid carriers (NLC) to improve its ocular bioavailability. (2) Methods: Firstly, MGN-NLC were prepared by the high shear homogenization coupled with the ultrasound (HSH-US) method. Finally, unloaded and MGN-loaded NLC were analyzed in terms of ocular tolerance. (3) Results: MGN-NLC showed good technological parameters suitable for ocular administration (particle size below 200 nm). The ORAC assay was performed to quantify the antioxidant activity of MGN, showing that the antioxidant activity of MGN-NLC (6494 ± 186 µM TE/g) was higher than that of the free compound (3521 ± 271 µM TE/g). This confirmed that the encapsulation of the drug was able to preserve and increase its activity. In ovo studies (HET-CAM) revealed that the formulation can be considered nonirritant. (4) Conclusions: Therefore, NLC systems are a promising approach for the ocular delivery of MGN.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Portadores de Fármacos / Sistemas de Liberación de Medicamentos / Nanotecnología / Xantonas / Nanoestructuras Idioma: En Revista: Molecules Asunto de la revista: BIOLOGIA Año: 2022 Tipo del documento: Article País de afiliación: Italia Pais de publicación: Suiza
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Portadores de Fármacos / Sistemas de Liberación de Medicamentos / Nanotecnología / Xantonas / Nanoestructuras Idioma: En Revista: Molecules Asunto de la revista: BIOLOGIA Año: 2022 Tipo del documento: Article País de afiliación: Italia Pais de publicación: Suiza